Castle Biosciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Castle Biosciences, Inc. (CSTL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income18.25-57.47-67.14-31.29-10.285.28
Depreciation & Amortization16.0012.3310.543.410.472.28
Deferred Income Tax1.40-0.22-1.88-8.740.000.00
Stock Based Compensation50.3251.2236.3221.748.310.00
Change in Working Capital-14.13-11.81-0.01-10.399.15-1.18
Change in Accounts Receivable-12.64-14.93-6.22-4.631.660.00
Change in Inventory-0.19-3.96-1.680.33-0.980.00
Change in Accounts Payable-4.375.710.58-0.180.170.00
Change in Other Working Capital0.270.647.310.388.300.00
Other Operating Activities0.2746.96-20.0121.821.382.32
Net Cash from Operating Activities64.87-5.63-41.66-18.989.877.02
Investing Activities
Capital Expenditures-28.3313.62-5.633.48-4.750.94
Acquisitions0.020.00-26.42-63.180.000.00
Purchases of Investments-205.73-189.08-134.690.000.000.00
Sales/Maturities of Investments183.90186.50-134.14-63.180.000.00
Other Investing Activities0.000.000.55-63.180.000.00
Net Cash from Investing Activities-50.14-16.18-166.55-66.66-4.75-0.94
Financing Activities
Debt Repayment-0.10-0.14-0.12-0.01-27.36-1.79
Common Stock Issued2.022.983.332.31333.2566.15
Common Stock Repurchased0.00-5.13-1.69-0.780.000.00
Other Financing Activities-8.76-5.13-1.69-0.780.000.00
Net Cash from Financing Activities6.14-2.301.525.42305.8988.29
Summary
Net Change in Cash20.87-24.11-206.69-80.22311.0194.37
Cash at Beginning of Period98.84122.95329.63409.8598.854.48
Cash at End of Period119.71-5.63122.95329.63409.8598.85
Free Cash Flow36.54-5.63-47.29-22.465.116.08
Supplemental Disclosures
Interest Paid0.430.010.020.001.982.21
Income Taxes Paid2.500.200.120.020.10-0.15